Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MUC16 (Mucin 16, Cell Surface Associated)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

MUC16 mutation	Non Small Cell Lung Cancer	MUC16 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 mutation	Melanoma	MUC16 mutation	Melanoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
MUC16 overexpression	Ovarian Cancer	MUC16 overexpression	Ovarian Cancer	ABT-888 Resistant: B - Late Trials ABT-888 Resistant : B	ABT-888 Resistant: B - Late Trials ABT-888 Resistant : B
MUC16-L	Pancreatic Ductal Adenocarcinoma	MUC16-L	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MUC16-L	Pancreatic Ductal Adenocarcinoma	MUC16-L	Pancreatic Ductal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3	regorafenib Resistant: C3 – Early Trials regorafenib Resistant : C3
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	trifluridine/tipiracil Resistant: C3 – Early Trials trifluridine / tipiracil Resistant : C3	trifluridine/tipiracil Resistant: C3 – Early Trials trifluridine / tipiracil Resistant : C3
MUC16 mutation	Melanoma	MUC16 mutation	Melanoma	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
MUC16 overexpression	Ovarian Cancer	MUC16 overexpression	Ovarian Cancer	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3	gemcitabine Sensitive: C3 – Early Trials gemcitabine Sensitive : C3
MUC16 overexpression	Ovarian Cancer	MUC16 overexpression	Ovarian Cancer	RG7882 Sensitive: C3 – Early Trials RG7882 Sensitive : C3	RG7882 Sensitive: C3 – Early Trials RG7882 Sensitive : C3